Quality Requirements for the Supply with Active Pharmaceutical Ingredients

BERLIN-CHEMIE MENARINI

- The API has to be produced, packaged, labelled, and QC-tested in accordance to the applicable DMF, CEP, pharmacopoeial monograph(s), and/or specifications specifically claimed by customer and in compliance with all applicable EU-GMP requirements (current versions always).

- Storage, handling, and distribution of the API has to be done in accordance to the storage conditions stated on the labels and in compliance with the applicable provisions of the DMF, CEP, and/or pharmacopoeial monograph(s) and all applicable EU-GMP and EU-GDP requirements (current versions always) in order to maintain the quality characteristics of the API, to exclude the possibility of deterioration, contamination, or mix-ups with any other material, and to ensure that test results remain applicable to the delivered API.

- The certificate of analysis has to be signed by a designated person of the quality unit with appropriate qualifications and experience whereas this signature assures that the batch has been checked for compliance with the specification.

- For suppliers of the API manufacturer an appropriate supplier management and qualification system has to be maintained, including a confirmation of the established supply chain and an adequate management system for changes linked to suppliers of the API manufacturer. Supply chain and traceability records have to be available and retained for each active substance (including active substance starting materials).

- Customer has to be informed of any significant changes to the manufacture of the API, which may have an impact on the quality of supplied API, and/or on any regulatory applications related to the API, and/or any changes to the established supply chain beginning from the API starting material in writing and within a reasonable time, prior to implementation, to allow customer to assess the potential impact of the change upon the API supplied or its use by customer.

- In case of quality incidents observed only *after* shipment of batches of the API, immediately after supplier has become aware of it, customer has to be informed in writing of any serious quality issue (independent whether observed internally or whether being notified by other customers or authorities) that could also have an impact on batches supplied to customer (e. g. regarding quality, health or safety) and/or may result in a recall of supplied API or finished drug product made thereof.

- Quality complaints have to be responded in a timely manner and in writing including the conclusions driven by the investigation performed and corrective/preventive actions defined. In case the investigation could not be finalized within 20 business days, an interim report has to be provided to customer.

- Every pharmaceutical raw materials order made by Berlin-Chemie AG is subject to these quality requirements. When accepting the order, the supplier agrees to the requirements of these contents and recognises them as binding.

authorized / date:	i.V. 27.02.2015	i.V. 25. FEB. 2015
	Maryam Hatami	**Dr. Christian Walz**
	Head of Quality Control and Qualified Person	Head of Quality Assurance

BERLIN-CHEMIE AG
Glienicker Weg 125
D-12489 Berlin